US gov­ern­ment to SCO­TUS: Take up the Te­va-GSK 'skin­ny' gener­ic drug la­bel case

The US So­lic­i­tor Gen­er­al is call­ing on the Supreme Court to take up a fierce­ly de­bat­ed case that could have a chill­ing ef­fect on gener­ic drug com­pa­nies’ will­ing­ness to bring their copy­cats to mar­ket un­der so-called “skin­ny” la­bels, mean­ing the gener­ic can on­ly be ap­proved for some of the ref­er­ence prod­uct’s in­di­ca­tions.

The case in ques­tion re­lates to GSK’s win over Te­va in a long-run­ning bat­tle over the gener­ic gi­ant’s skin­ny la­bel for GSK’s be­ta-block­er Coreg (carvedilol). At the time in 2007, Te­va’s gener­ic la­bel first in­clud­ed two of the three Coreg in­di­ca­tions, but Te­va did not ini­tial­ly win ap­proval for the third in­di­ca­tion for con­ges­tive heart fail­ure.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER